FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2751640892> ?p ?o ?g. }

• W2751640892 endingPage "967" @default.
• W2751640892 startingPage "958" @default.
• W2751640892 abstract "BACKGROUND: Few studies have assessed adherence to non-vitamin K antagonist oral anticoagulants (NOACs), especially using contemporary data now that multiple NOACs are available. OBJECTIVE: To compare adherence and treatment patterns among NOACs for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF). METHODS: Incident and treatment-naive NVAF patients were identified during 2013-2014 from a large claims database in this retrospective cohort study. Patients were included who initiated rivaroxaban, dabigatran, or apixaban within 30 days after diagnosis. Adherence to the index medication and adherence to any oral anticoagulant was assessed using the proportion of days covered (PDC) at 3, 6, and 9 months. The number of switches and gaps in therapy were also evaluated. Analyses were stratified by stroke risk scores, and a logistic regression model was used to control for factors that may predict high adherence. RESULTS: Dabigatran had lower adherence (PDC = 0.76, 0.64, 0.57) compared with rivaroxaban (PDC = 0.83, 0.73, 0.66; P < 0.001) and apixaban (PDC = 0.82, 0.72, 0.66; P < 0.001) at 3, 6, and 9 months of follow-up and twice the number of switches to either other anticoagulants or antiplatelet therapy. Adherence was higher overall as stroke risk increased, and dabigatran had consistently lower adherence compared with the other NOACs. Multivariable logistic regression predicting PDC ≥ 0.80 showed rivaroxaban users with higher odds of high adherence compared with dabigatran or rivaroxaban across all time periods. Adjusted analyses showed that increasing age and comorbid hypertension and diabetes were associated with higher adherence. CONCLUSIONS: In this real-world analysis of adherence to NOACs, rivaroxaban and apixaban had favorable unadjusted adherence profiles compared with dabigatran, while rivaroxaban users had higher odds of high adherence (PDC ≥ 0.80) among the NOACs in adjusted analyses. Clinicians and managed care organizations should consider the implications of lower adherence on clinical outcomes and quality assessment. DISCLOSURES: This project was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through grant number UL1TR000117. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The authors have nothing to disclose. Study concept and design were contributed by Brown and Shewale. Brown and Talbert collected the data, and data analysis was performed primarily by Brown, along with Shewale and Talbert. The manuscript was written primarily by Brown, along with Shewale, and revised by all the authors." @default.
• W2751640892 created "2017-09-15" @default.
• W2751640892 creator A5003167584 @default.
• W2751640892 creator A5012614682 @default.
• W2751640892 creator A5048193474 @default.
• W2751640892 date "2017-09-01" @default.
• W2751640892 modified "2023-10-05" @default.
• W2751640892 title "Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention for Newly Diagnosed and Treatment-Naive Atrial Fibrillation Patients: An Update Using 2013-2014 Data" @default.
• W2751640892 cites W1765682497 @default.
• W2751640892 cites W1797564483 @default.
• W2751640892 cites W1843312881 @default.
• W2751640892 cites W1934003446 @default.
• W2751640892 cites W1955685855 @default.
• W2751640892 cites W1957215797 @default.
• W2751640892 cites W1968218885 @default.
• W2751640892 cites W1975855508 @default.
• W2751640892 cites W1997689261 @default.
• W2751640892 cites W2016500724 @default.
• W2751640892 cites W2037445407 @default.
• W2751640892 cites W2053237747 @default.
• W2751640892 cites W2058611793 @default.
• W2751640892 cites W2061326496 @default.
• W2751640892 cites W2074206824 @default.
• W2751640892 cites W2075569506 @default.
• W2751640892 cites W2081764758 @default.
• W2751640892 cites W2088144189 @default.
• W2751640892 cites W2095151586 @default.
• W2751640892 cites W2105106824 @default.
• W2751640892 cites W2106143461 @default.
• W2751640892 cites W2118243040 @default.
• W2751640892 cites W2121394112 @default.
• W2751640892 cites W2121535135 @default.
• W2751640892 cites W2126206943 @default.
• W2751640892 cites W2127985968 @default.
• W2751640892 cites W2128428354 @default.
• W2751640892 cites W2140890791 @default.
• W2751640892 cites W2143575190 @default.
• W2751640892 cites W2152623033 @default.
• W2751640892 cites W2153938034 @default.
• W2751640892 cites W2162586165 @default.
• W2751640892 cites W2164643105 @default.
• W2751640892 cites W2171284718 @default.
• W2751640892 cites W2171420208 @default.
• W2751640892 cites W2178817764 @default.
• W2751640892 cites W2215377840 @default.
• W2751640892 cites W2260643844 @default.
• W2751640892 cites W2262020289 @default.
• W2751640892 cites W2292680795 @default.
• W2751640892 cites W2337365027 @default.
• W2751640892 cites W2347061888 @default.
• W2751640892 cites W2397301743 @default.
• W2751640892 cites W2419666630 @default.
• W2751640892 cites W2529460814 @default.
• W2751640892 cites W2541053720 @default.
• W2751640892 cites W2558300461 @default.
• W2751640892 cites W4205645630 @default.
• W2751640892 doi "https://doi.org/10.18553/jmcp.2017.23.9.958" @default.
• W2751640892 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5747360" @default.
• W2751640892 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28854077" @default.
• W2751640892 hasPublicationYear "2017" @default.
• W2751640892 type Work @default.
• W2751640892 sameAs 2751640892 @default.
• W2751640892 citedByCount "36" @default.
• W2751640892 countsByYear W27516408922018 @default.
• W2751640892 countsByYear W27516408922019 @default.
• W2751640892 countsByYear W27516408922020 @default.
• W2751640892 countsByYear W27516408922021 @default.
• W2751640892 countsByYear W27516408922022 @default.
• W2751640892 countsByYear W27516408922023 @default.
• W2751640892 crossrefType "journal-article" @default.
• W2751640892 hasAuthorship W2751640892A5003167584 @default.
• W2751640892 hasAuthorship W2751640892A5012614682 @default.
• W2751640892 hasAuthorship W2751640892A5048193474 @default.
• W2751640892 hasBestOaLocation W27516408921 @default.
• W2751640892 hasConcept C126322002 @default.
• W2751640892 hasConcept C127413603 @default.
• W2751640892 hasConcept C151956035 @default.
• W2751640892 hasConcept C156957248 @default.
• W2751640892 hasConcept C167135981 @default.
• W2751640892 hasConcept C2776301958 @default.
• W2751640892 hasConcept C2776704044 @default.
• W2751640892 hasConcept C2778661090 @default.
• W2751640892 hasConcept C2778810321 @default.
• W2751640892 hasConcept C2779161974 @default.
• W2751640892 hasConcept C2780638905 @default.
• W2751640892 hasConcept C2780645631 @default.
• W2751640892 hasConcept C71924100 @default.
• W2751640892 hasConcept C78519656 @default.
• W2751640892 hasConceptScore W2751640892C126322002 @default.
• W2751640892 hasConceptScore W2751640892C127413603 @default.
• W2751640892 hasConceptScore W2751640892C151956035 @default.
• W2751640892 hasConceptScore W2751640892C156957248 @default.
• W2751640892 hasConceptScore W2751640892C167135981 @default.
• W2751640892 hasConceptScore W2751640892C2776301958 @default.
• W2751640892 hasConceptScore W2751640892C2776704044 @default.
• W2751640892 hasConceptScore W2751640892C2778661090 @default.
• W2751640892 hasConceptScore W2751640892C2778810321 @default.
• W2751640892 hasConceptScore W2751640892C2779161974 @default.

• next